FLOW kidney outcomes trial results When added to standard care for diabetes and chronic kidney disease (CKD) , Ozempic reduced the likelihood of having a major kidney disease event such as losing more than half of ones kidney function, requiring dialysis, or needing a kidney transplant by 24%
Weinberg, Hallmarks of cancer: the next generation, Cell , vol
No one really knows
The Mod denotes a few amino acid modifications that help the peptide resist enzymatic breakdown
87 It is important to note that some of these cytokines can affect critical neural processes as it has been reported that cytokines such as IL-1 and IL-17, can inhibit neurogenesis in certain parts of the brain
After trials showed its drugs were successful at treating cardiovascular issues, Novo Nordiskthe maker of Ozempic and Wegovysuccessfully gained approval from the Food and Drug Administration in March to add cardiovascular benefits to Wegovys label